Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altor BioScience Corp.

This article was originally published in Start Up

Executive Summary

Altor BioSciences aims to exploit the intrinsic selectivity of T-cell receptors (TCRs) by pairing soluble receptors with therapeutic payloads. These TCR/drug combos are smaller than antibodies and could theoretically bind to targets within cells, not just on the cell surface, a main selling point of the firm's so-called STAR technology. At first Altor plans to enhance the safety and efficacy of existing marketed drugs by pairing them with monoclonal antibody-like TCRs for improved targeting.
Advertisement

Related Content

Cell Medica Ltd.
In Immunotherapy, Finally time for T Cells?
Adaptimmune Ltd.
Start-Up Previews (11/2008)
Start-Up Previews (11/2008)
In Immunotherapy, Finally time for T Cells?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel